DePuy Synthes/J&J is J&J MedTech division and one of the world's leading orthopedic suppliers.
DePuy Synthes — operating within Johnson & Johnson MedTech — is the world's largest orthopedic company by revenue with a comprehensive portfolio spanning joint reconstruction, trauma and extremities, spine, craniomaxillofacial, and surgical enabling technology. As part of J&J MedTech reporting approximately $34 billion in total MedTech revenues in 2025, DePuy Synthes benefits from J&J's global commercial infrastructure, regulatory capability, and financial resources. The Velys Robotic-Assisted Solution for total knee arthroplasty represents DePuy Synthes's primary competitive response to Stryker's Mako platform and has reached over 500 installed systems globally.
This report provides significant competitor information, analysis, and insight critical to the development and implementation of effective marketing and R&D programs.
Topics Covered
• Acquisitions and divestitures
• Marketing tactics
• Financial results
• Strengths and weaknesses
• Strategic directions
Table of Contents
1. Executive Summary
2. Company Overview and Business Model
3. Strategic Directions
4. Financial Results
5. SWOT Analysis
6. Technological Know-How and Key Products
7. Acquisitions and Divestitures
8. Marketing Tactics
9. Organization and Management
10. Appendix
List of Tables
Table 1. DePuy Synthes/J&J — Key Financial Metrics 2023-2025
Table 2. DePuy Synthes/J&J — Revenue by Segment 2023-2025
Table 3. DePuy Synthes/J&J — Revenue by Geography 2023-2025
Table 4. DePuy Synthes/J&J — SWOT Analysis
Table 5. DePuy Synthes/J&J — Key Products and Platforms 2025
Table 6. DePuy Synthes/J&J — M&A Activity 2020-2025
Table 7. DePuy Synthes/J&J — Key Management 2025
Table 8. DePuy Synthes/J&J — Strategic Priorities 2025-2030
